News | Heart Valve Technology | July 03, 2019

Study Shows Inducing a Heart Attack Helps Valve Patients

Henry Ford study uses septal alcohol ablation to thin out muscle near new mitral valve, eliminating left ventricular outflow track obstruction

Study Shows Inducing a Heart Attack Helps Valve Patients. This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates some of the tissue in the septum to allow for a larger LVOT area.

This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates (kills) some of the tissue in the cardiac septum to allow these valves to fit better and allow for an enlarged neo-LVOT for patients who otherwise could not receive this therapy. 

July 3, 2019 — A study of a procedure developed at Henry Ford Health System shows inducing a heart attack in patients with heart disease could be a viable option for patients in need of mitral valve replacement.

William W. O’Neill, M.D., medical director of the Henry Ford Center for Structural Heart Disease, and Dee Dee Wang, M.D., director of structural heart imaging for the center, developed the procedure with a team of cardiologists to address an often-fatal issue in transcatheter mitral valve replacement (TMVR). The study was published July 1 in Journal of the American College of Cardiology: Cardiovascular Interventions.1

In some patients with smaller heart chamber anatomy, using a catheter to thread a new valve into their heart and deploying it causes their native valve leaflet to block the flow of blood. This problem, called left ventricular outflow track (LVOT) obstruction, is nearly always fatal. 

“More than 50 percent of mitral valve patients are eliminated from TMVR trials due to LVOT obstruction,” O’Neill said. “So we were searching for a solution to save people’s lives. Inducing a ‘heart attack’ seems counterintuitive in cardiology. But this new procedure looks very promising.”

The team turned to alcohol septal ablation (ASA), a procedure used for the past 20 years to treat patients with thick, enlarged heart walls, or hypertrophic cardiomyopathy. Guided by high-definition, high-contrast ultrasound imaging done in real time, doctors performing ASA use a catheter to inject a tiny amount of alcohol into specific blood vessels feeding specific areas of the heart.

This process ‘kills’ the heart muscle in that targeted area, much like a naturally occurring heart attack when the vessels are blocked. The ensuing lack of blood to that area causes the muscle to lose mass and thin out. The thinning of certain areas of the heart allow it to function more efficiently, and often results in decrease of symptoms such as severe shortness of breath or angina.

When the same technique is used in the muscle near where the new mitral valve would be placed, the muscle thins, allowing more room for blood to flow after TMVR.

Key to the process has been imaging work by Wang, lead author of the study published. In landmark 2017 research that resulted in patented technology currently used during TMVR procedures, Wang established benchmark measurements of the LVOT opening that predict success or failure in TMVR. 

The July 1 study involved 30 patients with small LVOT openings who received ASA at six medical centers in the United States. Eight of the patients felt better after ASA and did not need the TMVR procedure. Twenty patients originally rejected for TMVR received the new valve after ASA, and their conditions improved. Two patients died; one had complications from a pacemaker and the other suffered multi-organ failure post-procedure from advanced illness.

“Patients now have hope because this gives them a new option,” said Wang. “We can widen that heart chamber area, so the patient has large enough area to insert a new valve.” 

Henry Kim, M.D., director of the Henry Ford Heart & Vascular Institute, said the procedure is the latest in many medical advances forged at the Center for Structural Heart Disease. “This is all part of our dedication to advancing the science of medicine,” said Kim. “Dr. O’Neill and the Center for Structural Heart Disease team was thinking outside the box again and applied that procedure to patients who have a lifesaving need. We’re grateful to support this work to help the sickest of patients.”

O’Neill performed the first transcatheter aortic valve replacement (TAVR) in the United States in 2005, and used an aortic valve to replace a mitral valve for the first time in the United States in 2013. He is one of 51 master fellows out of about 4,500 members in 70 nations of the Society for Cardiovascular Angiography and Interventions (SCAI), the largest group of interventional cardiologists in the world.

Read the article "Innovations in Cardiology at Henry Ford Hospital"

For more information: www.henryford.com/structuralheart

Reference

1. Wang D.D., Guerrero M., Eng M.H., et al. Alcohol Septal Ablation to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions, published online July 1, 2019. DOI: 10.1016/j.jcin.2019.02.034

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init